ARB or ACE Inhibitor: What's the Difference, and Why Did My Doctor Switch Me?

If you've ever filled a prescription and asked the pharmacist whether you're on an ACE inhibitor or an ARB, and gotten a slightly different answer than what you expected, you've stumbled into one of the most common confusions in cardiology medication. The two classes do almost the same thing. They have similar names, similar uses, and similar side effects most of the time. But there are real reasons doctors pick one over the other, and there's one specific reason your doctor may have switched you from one to the other without much explanation. I have this conversation with patients in clinic almost every week.

The short version is that both classes lower blood pressure and protect your heart and kidneys by interrupting the same process. They just turn the dial at different points along the chain. For most people, either class will work. The choice usually comes down to side effects, cost, and a few specific medical situations where one class has a bit more evidence behind it.

A One-Minute Explanation of What These Drugs Do

Your body has a built-in system for keeping blood pressure up. It's called the renin-angiotensin system, and you don't need to remember the name. The way it works is simple. When your body senses that pressure is dropping or that you're a little dehydrated, your kidneys send out a signal that triggers a chain of events. The end result is a hormone that does three things at once: it tightens up your blood vessels, it tells your kidneys to hold onto salt and water, and it pushes your heart and blood vessels to remodel over time.

In small doses, this system is helpful. It keeps you from passing out when you stand up too fast. It pulls fluid back during a stomach bug. The problem is when it stays switched on chronically, which happens with high blood pressure, heart failure, and certain kinds of kidney disease. Long-term activation damages the heart and the kidneys in ways that take years to play out but cost you function in the long run.

Both ACE inhibitors and ARBs interrupt that system. ACE inhibitors block the step where the hormone is made. ARBs block the step where the hormone tries to work on your blood vessels. Different points on the same line, similar end result. Blood pressure comes down. The heart works against less resistance. The kidneys are protected from the slow grind of high pressure.

Why We Have Two Classes That Do Almost the Same Thing

ACE inhibitors came first, in the 1980s. They were a major step forward and they're still excellent drugs. The names mostly end in "pril": lisinopril, ramipril, enalapril, benazepril, and so on. They work, they're cheap, and we have decades of experience with them.

There's one specific side effect that drove the development of the second class. ACE inhibitors block more than one thing in the body, and one of the side effects is a buildup of a chemical that irritates the airway. About one in ten patients on an ACE inhibitor develops a dry, tickly cough that won't quit. Cough drops don't help. Allergy medicine doesn't help. The cough is the medication. Once it starts, it doesn't go away as long as the medication continues.

ARBs were designed to do the same job without that side effect. They block the hormone at a different step, so they don't cause the chemical buildup that triggers the cough. The names of ARBs end in "sartan": losartan, valsartan, olmesartan, irbesartan, telmisartan, and so on. For someone who can't tolerate an ACE inhibitor because of cough, an ARB is the natural switch. The cough usually clears within a week or two of changing.

There's a much rarer but more serious problem ACE inhibitors can cause: sudden swelling of the lips, tongue, or throat. It's called angioedema and it's a true emergency when it involves the airway. ARBs are far less likely to cause this, though they can in rare cases. Anyone who's ever had angioedema on an ACE inhibitor needs to know never to take one again, and to be cautious about ARBs as a substitute.

Are They Truly Interchangeable

For everyday high blood pressure, mostly yes. Both classes lower blood pressure by similar amounts. Both protect against heart attack and stroke over years of use. Studies that put the two head to head, in patients with vascular disease and diabetes, found nearly identical outcomes. If one isn't working well or causing trouble, the other is a reasonable swap.

The biggest practical difference is the cough. Once it starts, the only fix is switching to an ARB. There's no way to predict who's going to develop the cough. Some people take an ACE inhibitor for years without any issue. Others develop the cough within a week. If it happens to you, it's not a sign of a more serious problem; it just means you're one of the people whose throat reacts to that particular medication.

A quick word on combining the two: don't. Putting an ACE inhibitor and an ARB together used to be tried in patients with stubborn heart failure or kidney disease. The studies came back showing more side effects without better outcomes, and the practice was abandoned. The exception is a newer combination drug for heart failure (more on that below) that pairs an ARB with a different mechanism, but that's not the same as stacking the two classes.

Where Each Class Is the First Choice

There are a few situations where I tend to start with an ACE inhibitor.

After a heart attack, particularly if a meaningful piece of the heart muscle was affected, ACE inhibitors have decades of evidence behind them showing they reduce the chance of dying or going into heart failure. For someone in the weeks after a heart attack, an ACE inhibitor is usually where I start.

For diabetic kidney disease with protein leaking into the urine, both classes work, but ACE inhibitors have the longest track record and are often the most affordable.

For someone with vascular disease (blockages in the arteries that feed the heart, brain, or legs) plus diabetes or other risk factors, ACE inhibitors have shown a clear edge in lowering the rate of heart attacks and strokes over years. That's a setting where I usually pick an ACE inhibitor.

There are also situations where I lean toward an ARB.

If a patient has tolerance trouble with ACE inhibitors (cough, mostly), an ARB is the obvious choice.

For Black patients on a single blood pressure medication, calcium channel blockers and water pills tend to work a bit better than either ACE inhibitors or ARBs alone. We still use ACE inhibitors and ARBs in this group, especially when there's heart failure or kidney disease in the picture, but they're often added on top of another medication rather than used by themselves.

For someone newly starting blood pressure treatment, with no past trouble, no compelling reason for one class or the other, an ARB is sometimes the more comfortable starting place because the cough risk is essentially zero. The cost difference between cheap ACE inhibitors and cheap ARBs has narrowed enough that price is rarely the deciding factor anymore.

Heart Failure: A Special Case

Heart failure with a weakened pumping function is an area where the conversation has shifted in the last decade. The old standard was an ACE inhibitor (or an ARB if cough was a problem) plus a beta blocker plus a water pill. That's still a reasonable backbone.

A newer combination medication, sold under the name Entresto, pairs an ARB with a second ingredient that boosts a protective natural hormone the heart makes when it's stressed. In a large trial in patients with weakened heart function, this combination performed better than the standard ACE inhibitor on its own. Patients hospitalized fewer times. Fewer died. The benefit was big enough that current heart failure guidelines list this combination as the preferred starting point in patients who can tolerate it and afford it.

For patients who can't get on Entresto because of cost or insurance, an ACE inhibitor or ARB is still a reasonable choice with strong evidence behind it. The full modern recipe for heart failure with weakened pumping is four medications: this RAAS-blocking drug (Entresto, ACE inhibitor, or ARB), a beta blocker, a diuretic-like medication called spironolactone, and a newer class called SGLT2 inhibitors. Each one helps, and the combination saves lives. Stopping any of them without a real reason is a bad idea.

Side Effects to Watch For

Both classes share most of the side effect profile. The differences are in degree, not in kind.

Cough is the big one for ACE inhibitors. Dry, tickly, won't quit. Switch to an ARB and it usually clears.

Both classes can raise potassium in the blood. For most people the rise is small and harmless. For people with kidney problems, diabetes, or anyone taking potassium supplements or certain other medications, the rise can be enough to cause muscle weakness or heart rhythm trouble. Routine bloodwork a couple of weeks after starting catches the problem early.

Both can cause a small, expected rise in your kidney lab numbers in the first few weeks. A small rise is the medication doing what it's supposed to do, and it doesn't mean your kidneys are being damaged. A bigger jump needs evaluation, and your doctor will tell you the threshold.

Both can cause low blood pressure or lightheadedness, especially in the first week or with dose increases. If you've been on a water pill or you're going through a stomach bug with vomiting and diarrhea, the combination can drop your pressure too far. Holding the medication for a day or two during a sick spell is reasonable; check with your doctor for a sick-day plan.

Neither class is safe in pregnancy. They can damage a developing baby's kidneys. If you're a woman of childbearing age, you need reliable contraception while on these medications, and you need to switch to a pregnancy-safe alternative as soon as you're planning to conceive or as soon as a pregnancy is confirmed.

Common Patient Questions

Why did my doctor switch me from lisinopril to losartan?

Almost always because of cough. If you developed a dry, persistent cough on lisinopril, the switch to losartan (an ARB) gets rid of it for nearly everyone. Less common reasons include angioedema (any sudden lip or tongue swelling on lisinopril warrants never going back to that class) or, occasionally, a personal preference of the prescriber based on insurance or cost.

Are ARBs really safer than ACE inhibitors?

Modestly, yes. ARBs cause cough less often, cause angioedema less often, and tend to be slightly better tolerated overall. The serious side effects that both classes share, like changes in potassium and kidney function, happen at similar rates. The pregnancy risk is the same. So in terms of day-to-day comfort, ARBs win a small margin.

Can I take potassium with my blood pressure medication?

Be careful. Both ACE inhibitors and ARBs raise potassium on their own. Adding a potassium supplement on top can push the level too high. If a doctor has told you to take potassium, your prescriber writing this medication needs to know, so the potassium dose can be adjusted or the supplement reconsidered. The same goes for salt substitutes, which usually contain potassium.

My kidney number went up. Should I stop?

Not on your own. A small bump in your creatinine number is expected when you start one of these medications and reflects a healthy effect inside the kidney filter. Over years, these medications protect kidneys from the long-term grind of high pressure. A bigger jump or a sudden change needs evaluation, and your doctor will work through the cause. Don't stop without talking to them.

Do I take this for the rest of my life?

For most reasons we use these drugs, yes. High blood pressure, heart failure, and diabetic kidney disease are long-term conditions, and the protection comes from steady use. Stopping resets the clock. There are short-term post-heart-attack scenarios where therapy is sometimes time-limited, but most patients on these medications stay on them indefinitely.

What should I do during a stomach bug?

If you're vomiting, having diarrhea, or unable to keep fluids down, holding the medication for a day or two is reasonable. The combination of dehydration plus the medication can drop your pressure too low and stress your kidneys. Resume normal dosing once you're eating and drinking again. If you have a written sick-day plan from your doctor, follow it. If not, call the office for guidance.

Is one drug in the class better than another within a class?

For most uses, the answer is no. Within ACE inhibitors, lisinopril and ramipril are common workhorses. Within ARBs, losartan and valsartan are common. The differences between the individual options are usually small (dosing convenience, half-life, what's covered by insurance). Your prescriber may pick one for a specific reason, but in most cases, the class matters more than the specific drug.

Can I drink alcohol on this medication?

In moderation, yes. Heavy alcohol can drop your pressure, dehydrate you, and interact poorly with most blood pressure medications. A drink or two with dinner generally isn't a problem. If you're at a wedding or a long event, slow your pace and stay hydrated.

When to Get Help Quickly

Call 911 right away for sudden swelling of the face, lips, tongue, or throat, or any difficulty breathing or swallowing after a dose. Throat and tongue swelling can close off the airway and is a true emergency. Stop the medication and don't take another dose until you've been seen.

Call your doctor's office the same day for severe lightheadedness, fainting, unexplained muscle weakness (which can be a sign of high potassium), or a clear drop in how much you're urinating after starting or adjusting the medication.

Call within a few days for a new dry cough that started after a recent ACE inhibitor, persistent dizziness on standing, or blood pressure readings at home that are running too high or too low. Routine bloodwork at one to two weeks after starting catches most of the silent issues, so don't skip that lab visit.

A Final Word

ACE inhibitors and ARBs are two of the most useful tools in modern cardiology. They lower blood pressure, protect the heart and kidneys over years, and reduce the chance of heart attack and stroke. The differences between the two classes are real but smaller than patients sometimes assume. For most situations, either class will get the job done, and the choice often comes down to side effects, cost, and a few specific medical settings where one has a touch more evidence.

If you're tolerating your current medication without trouble, the right move is to keep taking it. Don't stop because a friend had a different experience or because you saw something online. The protection these medications offer accumulates over years. A few weeks off resets the clock more than people realize.

If you're having side effects, talk to your prescriber. Most issues can be solved by switching within the class, switching to the other class, or adjusting the dose. The default move is rarely to stop entirely. The patients who do best long-term are the ones who stay engaged, ask questions, and keep their doctor in the loop. The medication only works if you're taking it.

References

1. McMurray, John J. V., Milton Packer, Akshay S. Desai, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, et al. "Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure." New England Journal of Medicine 371, no. 11 (2014): 993-1004.

2. Yusuf, Salim, Koon Teo, Janice Pogue, Leanne Dyal, Alvaro Avezum, Roberto Latini, Jeffrey L. Anderson, et al. "Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events." New England Journal of Medicine 358, no. 15 (2008): 1547-1559.

3. Yusuf, Salim, Peter Sleight, Janice Pogue, Jackie Bosch, Richard Davies, and Gilles Dagenais. "Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients." New England Journal of Medicine 342, no. 3 (2000): 145-153.

4. Pfeffer, Marc A., John J. V. McMurray, Eric J. Velazquez, Jean-Lucien Rouleau, Lars Kober, Aldo P. Maggioni, Scott D. Solomon, et al. "Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both." New England Journal of Medicine 349, no. 20 (2003): 1893-1906.

5. Pfeffer, Marc A., Karl Swedberg, Christopher B. Granger, Peter Held, John J. V. McMurray, Eric L. Michelson, Bertil Olofsson, Jan Ostergren, and Salim Yusuf. "Effects of Candesartan on Mortality and Morbidity in Patients with Chronic Heart Failure." Lancet 362, no. 9386 (2003): 759-766.

6. Whelton, Paul K., Robert M. Carey, Wilbert S. Aronow, Donald E. Casey Jr., Karen J. Collins, Cheryl Dennison Himmelfarb, Sondra M. DePalma, et al. "2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults." Journal of the American College of Cardiology 71, no. 19 (2018): e127-e248.

7. Heidenreich, Paul A., Biykem Bozkurt, David Aguilar, Larry A. Allen, Joni J. Byun, Monica M. Colvin, Anita Deswal, et al. "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure." Journal of the American College of Cardiology 79, no. 17 (2022): e263-e421.

8. CONSENSUS Trial Study Group. "Effects of Enalapril on Mortality in Severe Congestive Heart Failure." New England Journal of Medicine 316, no. 23 (1987): 1429-1435.

9. SOLVD Investigators. "Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure." New England Journal of Medicine 325, no. 5 (1991): 293-302.

10. Wright, Jackson T., Lawrence J. Fine, Daniel T. Lackland, Gbenga Ogedegbe, and Cheryl R. Dennison Himmelfarb. "Evidence Supporting a Systolic Blood Pressure Goal of Less Than 150 mm Hg in Patients Aged 60 Years or Older: The Minority View." Annals of Internal Medicine 160, no. 7 (2014): 499-503.

Published on damianrasch.com. The above information was composed by Dr. Damian Rasch, drawing on individual insight and bolstered by digital research and writing assistance. The information is for educational purposes only and does not constitute medical advice.